Rilmenidine (phosphate)

Rilmenidine phosphate, an innovative antihypertensive agent, is an orally active, selective I1 imidazoline receptor agonist. Rilmenidine phosphate is an alpha 2-adrenoceptor agonist. Rilmenidine phosphate induces autophagy. Rilmenidine phosphate acts both centrally by reducing sympathetic overactivity and in the kidney by inhibiting the Na+/H+ antiport. Rilmenidine phosphate modulates proliferation and stimulates the proapoptotic protein Bax thus inducing the perturbation of the mitochondrial pathway and apoptosis in human leukemic K562 cells [1][2][3].

Product Specifications

CAS Number

[85409-38-7]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Adrenergic Receptor; Apoptosis; Autophagy; Imidazoline Receptor

Type

Reference compound

Related Pathways

Apoptosis; Autophagy; GPCR/G Protein; Neuronal Signaling

Applications

Cancer-programmed cell death

Field of Research

Cancer; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/rilmenidine-phosphate.html

Purity

99.48

Solubility

DMSO : 5 mg/mL (ultrasonic; warming; heat to 80°C) |H2O : 83.33 mg/mL (ultrasonic)

Smiles

O=P(O)(O)O.C1(NC(C2CC2)C3CC3)=NCCO1

Molecular Formula

C10H19N2O5P

Molecular Weight

278.24

Precautions

H302, H315, H319, H335

References & Citations

[1]Reid JL. Rilmenidine: a clinical overview. Am J Hypertens. 2000;13 (6 Pt 2) :106S-111S.|[2]Srdic-Rajic T, et al. Rilmenidine suppresses proliferation and promotes apoptosis via the mitochondrial pathway in human leukemic K562 cells. Eur J Pharm Sci. 2016;81:172-180.|[3]Rose C, et al. Rilmenidine attenuates toxicity of polyglutamine expansions in a mouse model of Huntington's disease. Hum Mol Genet. 2010;19 (11) :2144-2153.